Pharma and Biotech Career Moves: Ardelyx Appoints New CMO

Ardelyx, Inc. Announced the appointment of Rajani Dinavahi, MD, as its new Chief Medical Officer on April 1, 2026. The biopharmaceutical company, which focuses on developing and commercializing medicines for significant unmet medical needs, intends to leverage Dr. Dinavahi’s experience to strengthen its clinical development and regulatory strategies.

Dr. Dinavahi joins the company with more than 20 years of experience in the biotechnology and healthcare sectors. Her professional background includes extensive work across several therapeutic modalities and areas, including nephrology, metabolic disease, autoimmune disorders, immuno-oncology, and transplantation.

Prior to her appointment at Ardelyx, Dr. Dinavahi served as the Senior Vice President and Chief Medical Officer at Atara Biotherapeutics. During her career, she has established a record of guiding medical programs through the entire development lifecycle, from early-stage research through Phase 3 clinical trials and final regulatory approval.

Strategic Focus on Unmet Medical Needs

The appointment comes as Ardelyx continues to target specific disease areas where existing treatment options remain insufficient for patients. The company currently focuses its research and development on two primary therapeutic areas:

• Chronic Kidney Disease with Hyperphosphatemia: This condition is estimated to affect the majority of patients with chronic kidney disease who are undergoing dialysis.
• Irritable Bowel Syndrome with Constipation (IBS-C): A gastrointestinal disorder marked by constipation and abdominal pain, which is often linked to a significant reduction in patient quality of life.

As part of its efforts in the gastrointestinal space, the company has published a review article demonstrating that tenapanor provides rapid and meaningful symptom relief for patients suffering from IBS-C.

Clinical Leadership and Pipeline Growth

Mike Raab, the president and chief executive officer of Ardelyx, stated that Dr. Dinavahi possesses a rare combination of scientific rigor, clinical expertise and proven leadership in advancing innovative therapies from development to patients.

As we enter an important phase of growth and execution, Rajani’s experience and vision will be instrumental in strengthening our pipeline, deepening our medical capabilities, and ensuring we continue to deliver meaningful outcomes for patients. I look forward to partnering closely with her as we build on our momentum and shape the next chapter of our company.

Mike Raab, President and CEO of Ardelyx

Dr. Dinavahi expressed that the company’s commitment to patient-focused innovation and the advancement of innovative therapies align with her own professional values. She noted that she is thrilled to join Ardelyx at such a pivotal time in its evolution and indicated her intention to help advance the company’s pipeline and maintain its current momentum.

The company operates under a set of core values described as inclusive, dedicated, passionate, and fearless. These values guide their approach to product innovation and community engagement, with a stated aim of delivering first-in-class medicines that utilize novel mechanisms to improve patient lives.